Menu

Hydroxyapatite

Also known as: Hydroxylapatite, Nano-hydroxyapatite

An oral-care calcium-phosphate material whose clinical performance and nano-particle safety must be assessed separately.

A matte gouache painting of a white paste swatch on a small ceramic tile with muted green brushwork.
Editorial illustration

Hydroxyapatite is a calcium-phosphate material used in oral care. One adult trial supported a particular toothpaste against a fluoride comparator within its noninferiority design. That does not prove every formula is equivalent, rebuild a lost tooth or establish safety for every nano-particle shape.1, 2

  • The adult trial lasted 18 months and used a 1,450-ppm fluoride comparator.1
  • Its prespecified noninferiority margin was 20 percentage points, not a test requiring identical outcomes.1
  • The final 2025 SCCS opinion applies only to defined rod-shaped, uncoated, non-surface-modified nano material; it excludes needle-shaped particles.2

What is Hydroxyapatite?

A shared mineral name does not specify particle size, shape, coating or the finished paste. Clinical caries outcomes and a material safety assessment answer different questions; neither can substitute for the other.1, 2

Where it comes from

Natural sources

  • Calcium-phosphate mineral related to the mineral phase of teeth and bone.

How it's made

Oral-care materials are manufactured with specific particle characteristics; the name alone is not a specification.

What it does in products

  • Particulate ingredient in toothpaste and mouthwash formulations

Benefits

Caries-prevention evidence is formulation-specific

limited evidence

The adult result supports further evaluation, not blanket equivalence across products and ages.1

The trial analyzed 189 adults in its intention-to-treat population and met its chosen noninferiority criterion. The margin and generally young participants limit generalization; three authors disclosed employment by Dr. Kurt Wolff GmbH & Co. KG.

Evidence scope and limitations

Oral-care hydroxyapatite: one adult caries trial and the final SCCS Submission IV nano-material opinion, with the U.S. intended-use framework.

  • A 20-percentage-point noninferiority margin is not proof of identical effectiveness; findings do not establish every age, caries-risk group or formula.
  • Three trial authors disclosed manufacturer employment; independent replication would improve confidence.
  • Nano safety applies only to specified rods and exposure conditions, not every particle or route. This is not an exhaustive hydroxyapatite literature review.

Evidence last checked: 2026-10-23

Side effects & safety

Safety depends on particle specification and exposure (varies)The SCCS conclusion is conditional on the assessed material, not an incidence estimate for all hydroxyapatite products.

Safety considerations

  • These sources do not provide a comprehensive medicine-interaction assessment.
  • Not for: Do not extend the nano safety conclusion to needle-shaped or differently coated particles.
  • Not for: A toothpaste study is not evidence that bulk powder should be swallowed or used as a calcium supplement.
2, 1

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In oral-care formulations

The final SCCS opinion assessed up to 29.5% in toothpaste and 10% in mouthwash for its specified nano material. These are assessment ceilings, not proven optimal clinical concentrations or home-formulation instructions. A consumer label may not provide enough particle detail to establish comparability.

2

Regulatory status

  • The SCCS opinion is a European cosmetic-ingredient safety assessment, not U.S. FDA authorization of an anticavity treatment. FDA classifies products by intended use; disease-prevention claims cannot be justified merely by calling the paste cosmetic.
2, 3

Three questions behind a mineral label

First identify the finished formula tested, then ask whether the particle specification matches the safety assessment. Finally consider the claim being made. A noninferiority result, a nano-material opinion and a promise to regrow a damaged tooth are not interchangeable evidence.

The practical editorial judgment is to resist a category-wide winner: a comparison depends on its margin, population and outcome. Safety permission does not measure cavity prevention, and an efficacy trial cannot clear untested particle shapes.

1, 2, 3

Frequently asked questions

Does nano-hydroxyapatite mean every nano form has been cleared?

No. The final SCCS conclusion is tied to specified rod dimensions and aspect-ratio distributions, with no coating or surface modification. Needle-shaped material is outside that conclusion.2

The bottom line

Ask which formula, which particle specification and which outcome were actually assessed.

References

  1. Paszynska E, Pawinska M, Enax J, et al.. Caries-preventing effect of a hydroxyapatite-toothpaste in adults: a 18-month double-blinded randomized clinical trial. Frontiers in Public Health (2023) · randomized trial · PMID 37533523; DOI 10.3389/fpubh.2023.1199728; NCT04756557; original trial, noninferiority margin and employee conflicts checked
  2. Scientific Committee on Consumer Safety. Scientific Opinion on Hydroxyapatite (nano), Submission IV: Final Opinion. European Commission / SCCS (2025) · safety assessment · SCCS/1677/25; final opinion adopted June 26, 2025, agency page published July 1, 2025; not the preliminary consultation draft
  3. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). U.S. Food and Drug Administration · government guidance · Undated agency resource; intended-use and toothpaste cosmetic/drug distinctions checked October 23, 2026

Revision history

  1. Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.